Back to Search
Start Over
Intravenous route to choroidal neovascularization by macrophage-disguised nanocarriers for mTOR modulation.
- Source :
- Acta Pharmaceutica Sinica B; May2022, Vol. 12 Issue 5, p2506-2521, 16p
- Publication Year :
- 2022
-
Abstract
- Retinal pigment epithelial (RPE) is primarily impaired in age-related macular degeneration (AMD), leading to progressive loss of photoreceptors and sometimes choroidal neovascularization (CNV). mTOR has been proposed as a promising therapeutic target, while the usage of its specific inhibitor, rapamycin, was greatly limited. To mediate the mTOR pathway in the retina by a noninvasive approach, we developed novel biomimetic nanocomplexes where rapamycin-loaded nanoparticles were coated with cell membrane derived from macrophages (termed as MRaNPs). Taking advantage of the macrophage-inherited property, intravenous injection of MRaNPs exhibited significantly enhanced accumulation in the CNV lesions, thereby increasing the local concentration of rapamycin. Consequently, MRaNPs effectively downregulated the mTOR pathway and attenuate angiogenesis in the eye. Particularly, MRaNPs also efficiently activated autophagy in the RPE, which was acknowledged to rescue RPE in response to deleterious stimuli. Overall, we design and prepare macrophage-disguised rapamycin nanocarriers and demonstrate the therapeutic advantages of employing biomimetic cell membrane materials for treatment of AMD. Macrophage-disguised nanoparticles are fabricated so as to deliver rapamycin to choroidal neovascularization lesions in the eye. The intravenous administration of the formulation addresses the issue of current therapeutic strategies that rely on the invasive intravitreal injection. [Display omitted] [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 22113835
- Volume :
- 12
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Acta Pharmaceutica Sinica B
- Publication Type :
- Academic Journal
- Accession number :
- 156942411
- Full Text :
- https://doi.org/10.1016/j.apsb.2021.10.022